NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Neonc Technologies, Inc.
InSightec
M.D. Anderson Cancer Center
Fundación GECP
Centre hospitalier de l'Université de Montréal (CHUM)
Duke University